[go: up one dir, main page]

WO2024258591A3 - Nouveaux inhibiteurs d'histones déméthylases et compositions et procédés associés - Google Patents

Nouveaux inhibiteurs d'histones déméthylases et compositions et procédés associés Download PDF

Info

Publication number
WO2024258591A3
WO2024258591A3 PCT/US2024/031283 US2024031283W WO2024258591A3 WO 2024258591 A3 WO2024258591 A3 WO 2024258591A3 US 2024031283 W US2024031283 W US 2024031283W WO 2024258591 A3 WO2024258591 A3 WO 2024258591A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
histone demethylases
novel inhibitors
demethylases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/031283
Other languages
English (en)
Other versions
WO2024258591A2 (fr
Inventor
Yibin Xiang
Robert E. MARTELL
Philip N. Tsichlis
Dagmar Ringe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2024258591A2 publication Critical patent/WO2024258591A2/fr
Publication of WO2024258591A3 publication Critical patent/WO2024258591A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention propose de nouveaux composés qui sont des inhibiteurs puissants et sélectifs d'histones déméthylases et des compositions pharmaceutiques, ainsi que des procédés associés pour traiter diverses maladies et troubles, tels que divers types de cancers.
PCT/US2024/031283 2023-06-14 2024-05-28 Nouveaux inhibiteurs d'histones déméthylases et compositions et procédés associés Pending WO2024258591A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363472833P 2023-06-14 2023-06-14
US63/472,833 2023-06-14

Publications (2)

Publication Number Publication Date
WO2024258591A2 WO2024258591A2 (fr) 2024-12-19
WO2024258591A3 true WO2024258591A3 (fr) 2025-01-23

Family

ID=93852827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/031283 Pending WO2024258591A2 (fr) 2023-06-14 2024-05-28 Nouveaux inhibiteurs d'histones déméthylases et compositions et procédés associés

Country Status (1)

Country Link
WO (1) WO2024258591A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101657A1 (en) * 2001-12-28 2005-05-12 Takeda Chemical Industries Ltd. Androgen receptor antagonists
US7968591B2 (en) * 2006-06-09 2011-06-28 Gruenenthal Gmbh 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use in medicaments
US9452168B2 (en) * 2008-04-24 2016-09-27 F2G Ltd Pyrrole antifungal agents
US20220227735A1 (en) * 2019-04-26 2022-07-21 Rutgers, The State University Of New Jersey Therapeutic methods and compounds
US11413272B2 (en) * 2017-05-26 2022-08-16 Oxford University Innovation Limited Inhibitors of metallo-beta-lactamases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101657A1 (en) * 2001-12-28 2005-05-12 Takeda Chemical Industries Ltd. Androgen receptor antagonists
US7968591B2 (en) * 2006-06-09 2011-06-28 Gruenenthal Gmbh 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use in medicaments
US9452168B2 (en) * 2008-04-24 2016-09-27 F2G Ltd Pyrrole antifungal agents
US11413272B2 (en) * 2017-05-26 2022-08-16 Oxford University Innovation Limited Inhibitors of metallo-beta-lactamases
US20220227735A1 (en) * 2019-04-26 2022-07-21 Rutgers, The State University Of New Jersey Therapeutic methods and compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem Compound 21 March 2021 (2021-03-21), "4-Ethyl-2-[4-ethyl-1-[(1-methylazetidin-3-yl)methyl]piperidin-3-yl]-1-[(1-methylazetidin-3-yl)methyl]piperazine", XP093267786, Database accession no. CID 167009811 *

Also Published As

Publication number Publication date
WO2024258591A2 (fr) 2024-12-19

Similar Documents

Publication Publication Date Title
WO2020102646A3 (fr) Inhibiteurs d'arg1 et/ou d'arg2
CR20240189A (es) Inhibidores de molécula pequeña de proteasa específica de ubiquitina 1 (usp1) y usos de los mismos
WO2024120378A3 (fr) Composés de triazole, procédés de préparation et utilisations médicinales de ceux-ci
EP4596048A3 (fr) Inhibiteurs de cd73
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
MX2021007247A (es) Derivados de rapamicina.
WO2018183631A8 (fr) Nouvelles formulations pharmaceutiques contenant de l'indirubine et des dérivés de celui-ci et procédés de fabrication et d'utilisation de celles-ci
NO20060392L (no) Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
BR112021022380A2 (pt) Inibidores de jak
CA3242612A1 (fr) Piperidinyl-methyl-purine amines enrichies en deuterium et composes associes et leur utilisation dans le traitement de maladies et d'etats
WO2023212612A3 (fr) Entités chimiques, compositions et procédés
MX2025007384A (es) Inhibidores de malt1
WO2024026481A3 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
WO2024026484A3 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
WO2024026479A3 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
WO2024026486A3 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
EP4424379A3 (fr) Inhibiteurs de bromodomaine à petites molécules et leurs utilisations
ZA202213890B (en) Compositions and methods for treating psychiatric disorders or symptoms thereof
WO2025049274A3 (fr) Dérivés tétracycliques, compositions et procédés associés
WO2024258591A3 (fr) Nouveaux inhibiteurs d'histones déméthylases et compositions et procédés associés
MX2023004008A (es) Derivados de tetrazol como inhibidores de trpa1.
ZA202100955B (en) Thrombin inhibitors, formulations, and uses thereof
PH12021550258A1 (en) Cdk8/19 inhibitors
WO2020154420A3 (fr) Dérivés d'acides aminés pour le traitement de maladies inflammatoires
BR112022005608A2 (pt) Inibidores de jak